ASCO 2019: First-line immunotherapy combinations in metastatic kidney cancer
This presentation from the American Society of Clinical Oncology (ASCO) [...]
ASCO 2019: Analysis of CARMENA trial results using IMDC risk groups
The results from CARMENA, a randomised phase III clinical trial [...]
A review of adjuvant therapy options for kidney cancer
In this paper, published in Current Treatment Options in Oncology [...]
Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer
A retrospective study using data from the International Metastatic Renal [...]
ASCO GU 2019: Interviews with the experts
The following interviews with kidney cancer experts were recorded by [...]
ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC
The results from the following study were presented at the [...]
ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)
Results from this trial for sarcomatoid renal cell carcinoma (RCC) [...]
Potential predictive biomarker of response to VEGF treatment in metastatic kidney cancer
A recent study published on PLOS/ONE has identified three genetic mutations/alterations [...]
ESOU 2019: First-line treatment for metastatic renal cell carcinoma – where do we stand?
The following review of the literature for first-line treatment of [...]
Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer
The following article from Practice Update discusses the JAVELIN Renal [...]
